ClinicalTrials.gg
TerminatedNCT00926575SUPPORTSUpdated Dec 6, 2013Results posted

Study of orBec® With Prednisone Therapy in the Treatment of Patients With Graft Versus Host Disease (GVHD)

A Phase 3 interventional study of oral beclomethasone 17,21-dipropionate and Placebo in Acute Gastrointestinal Graft vs Host Disease, sponsored by Soligenix. Terminated at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-12-06.

Sponsored by Soligenix · Phase 3, Interventional, and Treatment

Why this study was terminated
An independent Data Safety Monitoring Board recommended the study be stopped due to futility

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 454 studies in Graft vs Host Disease with a site in United States — 50 open to participants now, 71 under way, 2 of them phase 3. Graft vs Host Disease · United States.

Enrollment
32nd of 389
140 · median 30
Started
2009
with 13 others
Phase 3
40 of 454
2 open now
Registered
191st of 454
by date

Among the 454 studies in Graft vs Host Disease with a site in United States, this one is the 32nd largest by enrollment of the 389 interventional ones that give a count, is one of 14 that started in 2009, is one of 40 in phase 3, and was the 191st registered.

Graft vs Host Disease

804 studies on the registry are indexed under Graft vs Host Disease; 149 are open to participants now.

Browse Graft vs Host Disease studies →

Open to participants now

50 of the 454 studies in Graft vs Host Disease with a site in United States are open now. Recruiting first, the newest first:

45 more — sign in →

All 50 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 103 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 42 (41%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 454 studies in Graft vs Host Disease with a site in United States, or all of them as a file.
02

Study summary

Use of an oral topically-active glucocorticoid with limited side effects will control the gastrointestinal inflammatory process of GVHD and minimize glucocorticoid exposure.

03

Conditions studied

  • Acute Gastrointestinal Graft vs Host Disease

Browse trials for

Keywords

  • BDP
  • orBec
  • GVHD
  • beclomethasone dipropionate
  • bone marrow transplant
  • hematopoietic cell transplant
  • HCT
  • stem cell transplant
  • marrow transplant
  • SCT
  • beclomethasone 17,21-dipropionate
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Receipt of hematopoietic cell transplant
  • Diagnosis of GI graft vs. host disease ()
  • No GI infection
  • Must be able to swallow tablets
  • Must be able to read and understand
  • Adequate methods for the duration of the study

Exclusion criteria

Exclusion Criteria:

  • Significant Skin
  • Liver GVHD
  • Persistent vomiting
  • positive
  • Pregnancy/lactation
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
140 participants (actual)

Study arms

  • Experimental
    orBec®

    Investigational drug

    Drug: oral beclomethasone 17,21-dipropionate

  • Placebo comparator
    Placebo

    Control

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. The Proportion of Subjects With GVHD Treatment Failure

    The primary endpoint is the occurrence (yes, no) during the 80-day study period of GVHD treatment failure defined as use of prednisone or equivalent IV corticosteroids at doses higher than stated in the protocol, or use of any additional other glucocorticoid (including unblinded BDP) or addition of other immunosuppressant medications, in response to uncontrolled signs or symptoms of GVHD

    Time frame: Day 80

Secondary outcomes

  1. Cumulative Exposure to Prednisone

    Time frame: Day 80

  2. Survival Status

    Time frame: Day 200

07

Results

Posted Dec 6, 2013
Limitations and caveats
DSMB terminated study for futility; no safety concerns during analysis of patient population. Overall, 1 SAE considered possibly related to study drug, all others were not related to study drug.

Participant flow

Participant flow — Overall Study
MilestoneActivePlacebo
Started7070
Completed5453
Not completed1617
Withdrew: Adverse event11
Withdrew: Death44
Withdrew: Lost to follow-up11
Withdrew: Physician decision12
Withdrew: Protocol violation10
Withdrew: Withdrawal by subject89

Outcome measures

PrimaryThe Proportion of Subjects With GVHD Treatment Failure

The primary endpoint is the occurrence (yes, no) during the 80-day study period of GVHD treatment failure defined as use of prednisone or equivalent IV corticosteroids at doses higher than stated in the protocol, or use of any additional other glucocorticoid (including unblinded BDP) or addition of other immunosuppressant medications, in response to uncontrolled signs or symptoms of GVHD

Time frame:
Day 80

No measurements were reported for this outcome.

SecondaryCumulative Exposure to Prednisone
Time frame:
Day 80

No measurements were reported for this outcome.

SecondarySurvival Status
Time frame:
Day 200

No measurements were reported for this outcome.

Adverse events

Collected over Day 1 to Day 80. Non-serious events are listed at a 1.43% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Active—32/70 (45.7%)70/70 (100%)
Placebo—28/70 (40%)70/70 (100%)
Most frequent serious events
Showing 10 of 83
Most frequent serious events
EventActivePlacebo
DiarrheaGastrointestinal disorders4/702/70
FeverGeneral disorders2/701/70
NauseaGastrointestinal disorders2/701/70
VomitingGastrointestinal disorders2/701/70
CMV infectionInfections and infestations2/700/70
HyperglycaemiaMetabolism and nutrition disorders2/700/70
Renal failureRenal and urinary disorders2/701/70
Acute myeloid leukemia progressionBlood and lymphatic system disorders0/701/70
Angiopathic AnemiaBlood and lymphatic system disorders0/701/70
Leukemic RelapseBlood and lymphatic system disorders0/701/70
Most frequent other events
Showing 10 of 92
Most frequent other events
EventActivePlacebo
DiarrhoeaGastrointestinal disorders33/7017/70
NauseaGastrointestinal disorders22/7021/70
FatigueGeneral disorders17/7022/70
Abdominal painGastrointestinal disorders20/7014/70
HypertensionVascular disorders19/707/70
VomitingGastrointestinal disorders12/7017/70
Decreased appetiteMetabolism and nutrition disorders16/7013/70
Cytomegalovirus infectionInfections and infestations15/7011/70
PyrexiaGastrointestinal disorders12/709/70
HyperglycaemiaMetabolism and nutrition disorders11/7012/70

Baseline characteristics

DSMB terminated study for futility; no safety concerns during analysis of patient population. Overall, 1 SAE considered possibly related to study drug, all others were not related to study drug.

Age, Categorical
Age, Categorical(Participants)ActivePlaceboTotal
<=18 years000
Between 18 and 65 years6266128
>=65 years8412
Sex: Female, Male
Sex: Female, Male(Participants)ActivePlaceboTotal
Female343670
Male363470
08

Study locations

3 sites
  • Buffalo, New York, United States
  • Durham, North Carolina, United States
  • Seattle, Washington, United States
09

References and documents

Publications

  • McDonald GB, Bouvier M, Hockenbery DM, Stern JM, Gooley T, Farrand A, Murakami C, Levine DS. Oral beclomethasone dipropionate for treatment of intestinal graft-versus-host disease: a randomized, controlled trial. Gastroenterology. 1998 Jul;115(1):28-35. doi: 10.1016/s0016-5085(98)70361-0. PubMed 9649455 ↗
  • Hockenbery DM, Cruickshank S, Rodell TC, Gooley T, Schuening F, Rowley S, David D, Brunvand M, Berryman B, Abhyankar S, Bouvier M, McDonald GB. A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease. Blood. 2007 May 15;109(10):4557-63. doi: 10.1182/blood-2006-05-021139. Epub 2007 Jan 23. PubMed 17244684 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2009, a primary completion of Dec 2011 and a completion of May 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2013, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2009
First posted
Jun 23, 2009
Start
Oct 2009
Primary completionActual
Dec 2011
CompletionActual
May 2012
Results first posted
Dec 6, 2013
Last update
Dec 6, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00926575
Lead sponsor
Soligenix
Responsible party
Sponsor
First posted
Jun 23, 2009
Start date
Oct 2009
Primary completion
Dec 2011
Completion
May 2012
Results posted
Dec 6, 2013
Last update
Dec 6, 2013

Study contacts

Keith Sullivan, MD
principal investigator · Duke University
David Hockenbery, MD
principal investigator · Fred Hutchinson Cancer Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Beclomethasone

Start the discussion